AEON Biopharma Releases New Corporate Presentation

An announcement from AEON Biopharma ( (AEON) ) is now available.

On May 20, 2025, AEON Biopharma released a corporate presentation on its website, which may be used by management in future meetings. The presentation is not considered filed under the Securities Exchange Act of 1934, and its information is not subject to the liabilities of that section unless specifically incorporated by reference.

The most recent analyst rating on (AEON) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on AEON Biopharma stock, see the AEON Stock Forecast page.

Spark’s Take on AEON Stock

According to Spark, TipRanks’ AI Analyst, AEON is a Underperform.

AEON Biopharma is under significant financial distress, with negative profitability and cash flow challenges. While technical indicators show some stabilization, the overall bearish trend persists. The lack of profitability and absence of dividends weigh heavily on its valuation. The neutral earnings call impact slightly offsets these negatives but is insufficient to improve the overall outlook.

To see Spark’s full report on AEON stock, click here.

More about AEON Biopharma

AEON Biopharma, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing innovative therapeutic treatments.

Average Trading Volume: 3,302,959

Technical Sentiment Signal: Sell

Current Market Cap: $5.76M

For detailed information about AEON stock, go to TipRanks’ Stock Analysis page.